Castle Biosciences (CSTL) Q3 2024 earnings summary

Executive summary

• Q3 2024 revenue grew 39–39.5% year-over-year to $85.8 million, with total test report volume up 41–41.3% to 26,010, driven by strong adoption across dermatology, GI, and mental health segments.

• Net income for Q3 2024 was $2.3 million, reversing a net loss of $6.9 million in Q3 2023, reflecting operating leverage and improved gross margins.

• For the nine months ended September 30, 2024, net revenues rose 59.9% to $245.8 million, with net income of $8.7 million.

• Full-year 2024 revenue guidance raised to $320–330 million, reflecting 45–50% year-over-year growth.

• Focused on expanding test portfolio, commercial reach, and R&D pipeline, while maintaining strong liquidity and operational discipline.

Financial highlights

• Q3 2024 net revenues: $85.8 million (up 39–39.5% year-over-year); adjusted revenues: $86.3 million (up 42%).

• Gross margin for Q3 2024: 79–79.2%; adjusted gross margin: 81.9–82%.

• Adjusted EBITDA for Q3 2024 was $21.6 million, up from $6.6 million a year ago.

• Net income for Q3 2024: $2.3 million; EPS (diluted): $0.08.

• Cash, cash equivalents, and marketable securities as of September 30, 2024: $279.8 million.

Outlook and guidance

• Full-year 2024 revenue guidance increased to $320–330 million, up from prior $275–300 million.

• Management expects continued momentum and profitability, targeting operating cash flow positivity by end of 2025.

• Guidance assumes continued reimbursement for DecisionDx-SCC through nearly the entire fourth quarter.

• Fourth quarter volumes may be impacted by recent hurricanes, but updated guidance incorporates these assumptions.

• Anticipates launch of pipeline expansion, including an inflammatory skin disease test, by end of 2025.